The great thing is, from quick research on Kincell, manufacturing of CAR-T,s both autologous and allogeneic is in fact their specialty. That isn’t Imugene’s specialty. I think some here think we have handed off a major revenue resource, but in fact all that has happened is another probably much more qualified manufacturer can produce our new product when needed, in a contracted supply agreement, and as LC said, it will allow for IMU to concentrate on their core activities, accessing IMU’s very own AzerCel CAR-T,s as and when required for both trials and hopefully to hospitals for approved treatment further down the track.
I don’t see any negatives here. GLTAH. Onward.
Media Thread, page-13180
-
- There are more pages in this discussion • 1,486 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
0.005(9.26%) |
Mkt cap ! $433.6M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.9¢ | 5.4¢ | $1.489M | 25.99M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35252 | 5.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.0¢ | 1753430 | 24 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |